HIV Pre-Exposure Prophylaxis (PrEP) purchase patterns and STI occurrence among Israeli men: A cohort analysis

<h4>Background</h4> HIV Pre-exposure prophylaxis (PrEP) is the regular use of antiretroviral medication by people who are not infected with HIV to prevent seroconversion. Israel approved PrEP for continuous use in 2017, and Israeli Health Maintenance Organizations (HMO) offered PrEP with...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Daniel Chemtob, Clara Weil, Jordan Hannink Attal, Elias Hawila, Enav Noff Sadeh
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/d46ff7462faf47819bfe08f06e0995cb
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:d46ff7462faf47819bfe08f06e0995cb
record_format dspace
spelling oai:doaj.org-article:d46ff7462faf47819bfe08f06e0995cb2021-11-25T06:19:39ZHIV Pre-Exposure Prophylaxis (PrEP) purchase patterns and STI occurrence among Israeli men: A cohort analysis1932-6203https://doaj.org/article/d46ff7462faf47819bfe08f06e0995cb2021-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601516/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4> HIV Pre-exposure prophylaxis (PrEP) is the regular use of antiretroviral medication by people who are not infected with HIV to prevent seroconversion. Israel approved PrEP for continuous use in 2017, and Israeli Health Maintenance Organizations (HMO) offered PrEP with a copayment to eligible members. <h4>Methodology</h4> This retrospective cohort study included all people who were dispensed PrEP between September 2017 to June 2019 in the second largest HMO in Israel. Statistical analysis, including Kaplan Meier, was conducted to evaluate user PrEP purchase, adherence to medical follow-up, and clinical outcomes. <h4>Results</h4> In total, a cohort of 757 PrEP users were followed for 657.8 person-years. All but one user were male; median age was 35 years. At baseline, 0.8% had gonorrhea and 1.5% had chlamydia infections and 4.4% had recent syphilis infection. Continuous use of PrEP (without interruption/discontinuation) was observed in 29.9%, while 39.9% interrupted and 30.3% discontinued use. Median time to first interruption/discontinuation was 4.0 months. At 6–12 months after initiation, 79.8% of users had a documented HIV test, 77.3% a Chlamydia-Gonorrhea panel, and 78.9% a creatinine test. There was one new case of HIV among the cohort, five months after PrEP discontinuation. Estimated first-year infection rates were 5.0%, 8.6% and 6.8% for gonorrhea, chlamydia and first-time syphilis, respectively. <h4>Conclusions</h4> This study shows heterogeneous PrEP purchase patterns and required medical follow-up, and an increase in STIs among consistent PrEP users. Improving adherence to recommended medical follow-up during PrEP use is essential in PrEP’s integration into Israel’s national HIV prevention strategy.Daniel ChemtobClara WeilJordan Hannink AttalElias HawilaEnav Noff SadehPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 11 (2021)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Daniel Chemtob
Clara Weil
Jordan Hannink Attal
Elias Hawila
Enav Noff Sadeh
HIV Pre-Exposure Prophylaxis (PrEP) purchase patterns and STI occurrence among Israeli men: A cohort analysis
description <h4>Background</h4> HIV Pre-exposure prophylaxis (PrEP) is the regular use of antiretroviral medication by people who are not infected with HIV to prevent seroconversion. Israel approved PrEP for continuous use in 2017, and Israeli Health Maintenance Organizations (HMO) offered PrEP with a copayment to eligible members. <h4>Methodology</h4> This retrospective cohort study included all people who were dispensed PrEP between September 2017 to June 2019 in the second largest HMO in Israel. Statistical analysis, including Kaplan Meier, was conducted to evaluate user PrEP purchase, adherence to medical follow-up, and clinical outcomes. <h4>Results</h4> In total, a cohort of 757 PrEP users were followed for 657.8 person-years. All but one user were male; median age was 35 years. At baseline, 0.8% had gonorrhea and 1.5% had chlamydia infections and 4.4% had recent syphilis infection. Continuous use of PrEP (without interruption/discontinuation) was observed in 29.9%, while 39.9% interrupted and 30.3% discontinued use. Median time to first interruption/discontinuation was 4.0 months. At 6–12 months after initiation, 79.8% of users had a documented HIV test, 77.3% a Chlamydia-Gonorrhea panel, and 78.9% a creatinine test. There was one new case of HIV among the cohort, five months after PrEP discontinuation. Estimated first-year infection rates were 5.0%, 8.6% and 6.8% for gonorrhea, chlamydia and first-time syphilis, respectively. <h4>Conclusions</h4> This study shows heterogeneous PrEP purchase patterns and required medical follow-up, and an increase in STIs among consistent PrEP users. Improving adherence to recommended medical follow-up during PrEP use is essential in PrEP’s integration into Israel’s national HIV prevention strategy.
format article
author Daniel Chemtob
Clara Weil
Jordan Hannink Attal
Elias Hawila
Enav Noff Sadeh
author_facet Daniel Chemtob
Clara Weil
Jordan Hannink Attal
Elias Hawila
Enav Noff Sadeh
author_sort Daniel Chemtob
title HIV Pre-Exposure Prophylaxis (PrEP) purchase patterns and STI occurrence among Israeli men: A cohort analysis
title_short HIV Pre-Exposure Prophylaxis (PrEP) purchase patterns and STI occurrence among Israeli men: A cohort analysis
title_full HIV Pre-Exposure Prophylaxis (PrEP) purchase patterns and STI occurrence among Israeli men: A cohort analysis
title_fullStr HIV Pre-Exposure Prophylaxis (PrEP) purchase patterns and STI occurrence among Israeli men: A cohort analysis
title_full_unstemmed HIV Pre-Exposure Prophylaxis (PrEP) purchase patterns and STI occurrence among Israeli men: A cohort analysis
title_sort hiv pre-exposure prophylaxis (prep) purchase patterns and sti occurrence among israeli men: a cohort analysis
publisher Public Library of Science (PLoS)
publishDate 2021
url https://doaj.org/article/d46ff7462faf47819bfe08f06e0995cb
work_keys_str_mv AT danielchemtob hivpreexposureprophylaxispreppurchasepatternsandstioccurrenceamongisraelimenacohortanalysis
AT claraweil hivpreexposureprophylaxispreppurchasepatternsandstioccurrenceamongisraelimenacohortanalysis
AT jordanhanninkattal hivpreexposureprophylaxispreppurchasepatternsandstioccurrenceamongisraelimenacohortanalysis
AT eliashawila hivpreexposureprophylaxispreppurchasepatternsandstioccurrenceamongisraelimenacohortanalysis
AT enavnoffsadeh hivpreexposureprophylaxispreppurchasepatternsandstioccurrenceamongisraelimenacohortanalysis
_version_ 1718413894296272896